• LAST PRICE
    5.4700
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-0.7260%)
  • Bid / Lots
    5.3800/ 1
  • Ask / Lots
    5.7400/ 1
  • Open / Previous Close
    5.5000 / 5.5100
  • Day Range
    Low 5.3786
    High 5.7299
  • 52 Week Range
    Low 2.0980
    High 58.6000
  • Volume
    37,231
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 5.51
TimeVolumePRTG
09:32 ET7535.5
09:45 ET1005.59
09:50 ET1005.585
10:03 ET6005.59
10:06 ET9005.6505
10:15 ET3005.65
10:17 ET4105.6017
10:21 ET1005.6414
10:26 ET9005.644
10:28 ET5415.65
10:39 ET1005.72
10:50 ET2005.55
10:55 ET8855.69
11:00 ET3005.67
11:02 ET11005.67
11:06 ET2005.4859
11:15 ET8725.5
11:42 ET10005.5398
11:47 ET1005.68
11:49 ET11005.57
11:54 ET7505.57
12:00 ET1005.6105
12:03 ET1005.6799
12:05 ET1005.46
12:27 ET1235.5283
12:50 ET21195.58
12:54 ET12005.57
12:59 ET33455.57
01:06 ET2005.45
01:19 ET54995.4302
01:48 ET1345.3786
02:02 ET37995.58
03:32 ET10005.57
03:38 ET1005.465
03:56 ET2005.47
03:59 ET3425.47
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRTG
Portage Biotech Inc
5.8M
-0.1x
---
United StatesABTI
Alterola Biotech Inc
5.8M
-2.4x
---
United StatesNLSP
NLS Pharmaceutics AG
5.7M
-0.4x
---
United StatesKTTA
Pasithea Therapeutics Corp
5.6M
-0.3x
---
United StatesNCNA
NuCana PLC
4.5M
0.0x
---
United StatesTCBP
TC Biopharm (Holdings) PLC
4.0M
0.0x
---
As of 2024-10-08

Company Information

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.

Contact Information

Headquarters
Clarence Thomas Building, Road Town P.O. Box 4649TORTOLA, ON, Virgin Islands (British) VG1110
Phone
416-929-1806
Fax
416-929-6612

Executives

Chairman of the Board, Chief Executive Officer
Ian Walters
Chief Financial Officer, Secretary
Allan Shaw
Chief Scientific Officer
Robert Kramer
Vice President - Project Management and Operations
Steven Innaimo
Vice President - Development
Justin Fairchild

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.8M
Revenue (TTM)
$0.00
Shares Outstanding
1.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-68.81
Book Value
$4.07
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.